Stephen Michael Moore, the Senior Vice President and Chief Legal Officer at Personalis, Inc. (NASDAQ:PSNL), a company currently valued at $252 million, recently sold shares of the company, according to a Form 4 filing with the SEC. According to InvestingPro data, PSNL has shown remarkable performance with a 168% return over the past year, though the stock remains undervalued based on Fair Value analysis. On December 16, Moore sold 1,513 shares of Personalis common stock at an average price of $3.82 per share, amounting to a total transaction value of approximately $5,779.
The shares were automatically sold to cover tax withholding obligations from the settlement of vested restricted stock units. Following this transaction, Moore holds 65,875 shares of Personalis. The sale price ranged from $3.65 to $3.91 per share.
In other recent news, Personalis, Inc. reported a significant 41% increase in year-over-year revenue for Q3 2024, amounting to $25.7 million. This growth was primarily driven by a 96% surge in biopharma sector revenue, attributed to the demand for their tumor profiling products and the NeXT Personal MRD assay. The company ended the quarter with $143.7 million in cash, projected to fund operations into the first half of 2027. Notably, Personalis raised its full-year revenue guidance to between $83 million and $84 million, reflecting confidence in its strategic growth and the efficacy of its MRD testing solutions. However, Q4 revenue is projected to decline to between $15 million and $16 million, mainly due to a decrease in revenue from Moderna (NASDAQ:MRNA) and Natera (NASDAQ:NTRA). Despite this, the company's gross margin improved to 34% in Q3, up from 19.1% year-over-year. These are among the recent developments that continue to shape the company's financial landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.